CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

de Graan, Anne-Joy M;Elens, Laure;Sprowl, Jason A;Sparreboom, Alex;van Schaik, Ron H N;et.al.
(2013) Clinical Cancer Research —

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 226.91 KB
Request a copy

Details

Authors
  • de Graan, Anne-Joy M
    Author
  • Elens, LaureUCLouvain
    Author
  • Sprowl, Jason A
    Author
  • Sparreboom, Alex
    Author
  • van Schaik, Ron H N
    Author
Show more
Abstract
Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

de Graan, A.-J. M., Elens, L., Sprowl, J. A., Sparreboom, A., Friberg, L. E., van der Holt, B., de Raaf, P. J., de Bruijn, P., Engels, F. K., Eskens, F. A. L. M., Wiemer, E. A. C., Verweij, J., Mathijssen, R. H. J., & van Schaik, R. H. N. (2013). CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-12-3786